BR112017024997A2 - tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1 - Google Patents

tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1

Info

Publication number
BR112017024997A2
BR112017024997A2 BR112017024997-9A BR112017024997A BR112017024997A2 BR 112017024997 A2 BR112017024997 A2 BR 112017024997A2 BR 112017024997 A BR112017024997 A BR 112017024997A BR 112017024997 A2 BR112017024997 A2 BR 112017024997A2
Authority
BR
Brazil
Prior art keywords
treatment
hyperinsulinemic
glp1ra
prevention
adverse effects
Prior art date
Application number
BR112017024997-9A
Other languages
English (en)
Inventor
L. Mclaughlin Tracey
M. Craig Colleen
Original Assignee
The Bot Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Bot Of The Leland Stanford Junior University filed Critical The Bot Of The Leland Stanford Junior University
Publication of BR112017024997A2 publication Critical patent/BR112017024997A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Abstract

o tratamento da hipoglicemia hiperinsulinêmica compreende a administração de uma quantidade eficaz de um antagonista do receptor do peptídeo 1 semelhante ao glucagon (glp1ra) sozinho ou em combinação com um agente ou amilinomimético ou qualquer agente contra o esvaziamento gástrico. pacientes que sofrem de hipoglicemia hiperinsulinêmica após cirurgia bariátrica experimentam um benefício específico, uma vez que não existe atualmente um método eficaz para seu tratamento. a prevenção ou redução de efeitos adversos agudos da hipoglicemia pós-prandial, como palpitações, tremor, fraqueza, sudorese, confusão, fadiga, visão turva, convulsões ou perda de consciência, e a prevenção de efeitos adversos crônicos da hipoglicemia hiperinsulinêmica, como comprometimento cognitivo, podem ser obtidas com glp1ra.
BR112017024997-9A 2015-05-22 2016-05-23 tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1 BR112017024997A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US62/165,743 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US62/254,175 2015-11-11
US201662329850P 2016-04-29 2016-04-29
US62/329,850 2016-04-29
PCT/US2016/033836 WO2016191394A1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with glp-1 antagonists

Publications (1)

Publication Number Publication Date
BR112017024997A2 true BR112017024997A2 (pt) 2018-07-31

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112017024997-9A BR112017024997A2 (pt) 2015-05-22 2016-05-23 tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1
BR112017025000-4A BR112017025000A2 (pt) 2015-05-22 2016-05-23 tratamento de hipoglicemia pós-bariátrica com exendina (9-39)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017025000-4A BR112017025000A2 (pt) 2015-05-22 2016-05-23 tratamento de hipoglicemia pós-bariátrica com exendina (9-39)

Country Status (17)

Country Link
US (8) US10660937B2 (pt)
EP (4) EP3936143A1 (pt)
AU (4) AU2016267052B2 (pt)
BR (2) BR112017024997A2 (pt)
CA (2) CA3024353A1 (pt)
CL (2) CL2017002913A1 (pt)
CY (2) CY1124616T1 (pt)
DK (2) DK3297654T3 (pt)
ES (2) ES2887723T3 (pt)
HR (2) HRP20211768T1 (pt)
HU (2) HUE057301T2 (pt)
LT (2) LT3297653T (pt)
PL (2) PL3297654T3 (pt)
PT (2) PT3297653T (pt)
RS (2) RS62627B1 (pt)
SI (2) SI3297654T1 (pt)
WO (2) WO2016191395A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3456340T3 (da) 2007-01-08 2022-03-21 Univ Pennsylvania Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme
US10660937B2 (en) 2015-05-22 2020-05-26 The Board Of Trustees Of The Leland Stanford Junio Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2018094404A1 (en) 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
JP7444786B2 (ja) * 2018-01-23 2024-03-06 ゼリス ファーマシューティカルズ インコーポレイテッド 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
EP4233842A3 (en) * 2018-10-15 2023-10-25 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia
WO2020144378A1 (en) * 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138161C (en) 1992-06-15 2003-10-21 Glenn C. Andrews Glucagon-like peptide and insulinotropin derivatives
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1629849B2 (en) 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Pharmaceutical compositions comprising exendins and agonists thereof
CZ297361B6 (cs) 1998-01-30 2006-11-15 Novo Nordisk A/S Injekcní stríkacka
DE69923587T2 (de) 1998-12-10 2005-06-23 Agouron Pharmaceuticals, Inc., La Jolla Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
AU770712B2 (en) 1999-01-14 2004-02-26 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
KR100675711B1 (ko) 1999-01-14 2007-02-01 아밀린 파마슈티칼스, 인크. 신규 엑센딘 아고니스트 제제 및 이의 투여 방법
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
JP4398644B2 (ja) 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ＥｒｂＢ界面ペプチド擬態およびその使用方法
MXPA04001560A (es) 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
ES2727854T3 (es) 2003-11-20 2019-10-21 Novo Nordisk As Formulaciones de péptidos que contienen propilenglicol que son óptimas para la producción y para su uso en dispositivos de inyección
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
EA200601904A1 (ru) 2004-04-15 2007-02-27 Алкермес, Инк. Система отсроченного высвобождения лекарственного средства на основе полимеров
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
EP1888031B1 (en) 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
SI1971362T1 (sl) 2005-08-19 2015-03-31 Amylin Pharmaceuticals, Llc Eksendin za zdravljenje diabetesa in zmanjšanje telesne mase
CA2652907A1 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Compositions and methods for treatment of diabetes
DK3456340T3 (da) 2007-01-08 2022-03-21 Univ Pennsylvania Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
JP5128658B2 (ja) 2007-04-05 2013-01-23 テクファーマ・ライセンシング・アクチェンゲゼルシャフト 機能的な駆動素子を備える投与装置
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
AU2009245294B2 (en) 2008-05-05 2014-02-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2552646T3 (es) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendinas para disminuir el colesterol y los triglicéridos
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
JP5721624B2 (ja) 2008-07-08 2015-05-20 ノバルティス アーゲー 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
US8846612B2 (en) 2009-04-03 2014-09-30 Nestec S.A. Promotion of healthy catch-up growth
DK2440228T3 (en) 2009-06-08 2018-12-17 Amunix Operating Inc Glucose regulating polypeptides and methods for their preparation and use
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
US20150005233A1 (en) 2012-02-08 2015-01-01 Seneb Biosciences, Inc. Treatment of hypoglycemia
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10660937B2 (en) 2015-05-22 2020-05-26 The Board Of Trustees Of The Leland Stanford Junio Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2018094404A1 (en) 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Also Published As

Publication number Publication date
EP3297654A1 (en) 2018-03-28
CA3024353A1 (en) 2016-12-01
EP3297653A4 (en) 2018-12-26
ES2887723T3 (es) 2021-12-27
EP3936143A1 (en) 2022-01-12
CL2017002913A1 (es) 2018-06-01
HUE055728T2 (hu) 2021-12-28
US20210290731A1 (en) 2021-09-23
PL3297654T3 (pl) 2021-12-20
PL3297653T3 (pl) 2022-01-31
EP3297653B1 (en) 2021-09-15
AU2016267057A1 (en) 2017-12-14
US10639354B2 (en) 2020-05-05
EP3297654A4 (en) 2018-04-11
HRP20211768T1 (hr) 2022-02-18
US11622995B2 (en) 2023-04-11
EP3978011A1 (en) 2022-04-06
EP3297653A1 (en) 2018-03-28
AU2016267052A1 (en) 2017-12-14
AU2016267052B2 (en) 2022-01-20
WO2016191394A1 (en) 2016-12-01
WO2016191395A1 (en) 2016-12-01
US20200276271A1 (en) 2020-09-03
RS62368B1 (sr) 2021-10-29
LT3297654T (lt) 2021-10-25
US20200276272A1 (en) 2020-09-03
US20210315974A1 (en) 2021-10-14
US11617782B2 (en) 2023-04-04
CL2017002911A1 (es) 2018-05-25
SI3297654T1 (sl) 2021-11-30
BR112017025000A2 (pt) 2018-08-07
AU2022201973A1 (en) 2022-04-14
LT3297653T (lt) 2022-01-10
AU2022202506A1 (en) 2022-05-12
HRP20211285T1 (hr) 2022-01-07
CY1125147T1 (el) 2023-03-24
PT3297653T (pt) 2021-10-25
US10993992B2 (en) 2021-05-04
PT3297654T (pt) 2021-09-06
US10993991B2 (en) 2021-05-04
US20180117122A1 (en) 2018-05-03
EP3297654B1 (en) 2021-07-07
US10660937B2 (en) 2020-05-26
DK3297653T3 (da) 2021-10-18
US20230346890A1 (en) 2023-11-02
CY1124616T1 (el) 2022-07-22
SI3297653T1 (sl) 2022-01-31
ES2897955T3 (es) 2022-03-03
US20240000894A1 (en) 2024-01-04
DK3297654T3 (da) 2021-09-06
US20180147261A1 (en) 2018-05-31
CA3024358A1 (en) 2016-12-01
AU2016267057B2 (en) 2021-12-23
RS62627B1 (sr) 2021-12-31
HUE057301T2 (hu) 2022-05-28

Similar Documents

Publication Publication Date Title
BR112017024997A2 (pt) tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1
MY191321A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
TN2017000426A1 (en) Pharmaceutical compositions for combination therapy
BR112015001158A2 (pt) formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia
BR112017008093A2 (pt) processos para tratamento de doenças oculares
TN2017000271A1 (en) Glucagon derivative having improved stability
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MX2020001342A (es) Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
MX366685B (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
EP3758689A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF HYPOGLYCEMIA IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES
Desai et al. Comparison of the antiemetic effect of ramosetron with the combination of dexamethasone and ondansetron in middle ear surgery: A double-blind, randomized clinical study
EP3737381A4 (en) MEDICAL DEVICE AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AN EYE DISEASE OR DISEASE
WO2019118779A3 (en) Peptides and other agents for treating pain and increasing pain sensitivity
MX2020005007A (es) Combinaciones farmaceuticas y metodos para el tratamiento de diabetes y trastornos asociados.
Devor et al. PNS origin of phantom limb sensation and pain: Reply to Letter to the Editor regarding Foell et al., Peripheral origin of phantom limb pain: Is it all resolved?
MX2020006658A (es) Tratamiento de hipoglucemia inducida por el ejercicio en la diabetes tipo 1 y tipo 2 en la que se usa insulina.
Santos et al. Pharmacological approach for the management of patient with carpal tunnel syndrome associated to diabetic polyneuropathy. Case report
PH12020551311A1 (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
AR102494A1 (es) Métodos para tratar enfermedades oculares
Colak Anaphylactic shock: case report
Schreiber et al. (315) Pain modulation in chronic pain patients: the relationship of pain sensitivity, pain inhibition, and distraction analgesia
Ansari Toxic epitheliopathy in an elderly patient: case report

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]